Want to see HK:2898 full AI Analyst Report?
Top Page
Sunho Biologics,Inc.
(2898)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$6.00
▼(-8.95% Downside)
Action:Reiterated
Date:01/30/26
The score is weighed down primarily by severe financial weakness (sharp revenue decline, large losses, and negative cash flows). Technical indicators also remain bearish with the stock trading below key moving averages and a negative MACD. Valuation offers limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Low leverage
Relatively low reported debt-to-equity gives the company more financial flexibility to endure prolonged R&D cycles and pursue financing without immediate solvency pressure. Over 2–6 months, limited leverage reduces bankruptcy risk and preserves capacity to raise growth capital if needed.
Negative Factors
Severe revenue collapse
A ~98% revenue decline is a structural red flag: it erodes core cash generation, undermines commercial viability, and limits ability to fund operations and R&D internally. Over several months this magnifies funding needs and raises execution risk for product development and commercialization plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Relatively low reported debt-to-equity gives the company more financial flexibility to endure prolonged R&D cycles and pursue financing without immediate solvency pressure. Over 2–6 months, limited leverage reduces bankruptcy risk and preserves capacity to raise growth capital if needed.
Read all positive factors
Sunho Biologics,Inc. (2898) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$970.43M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)-0.15
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees130
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.54
Shares Outstanding156,666,800
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.89
Price to Sales (P/S)11985.90
P/FCF Ratio-2.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sunho Biologics,Inc. Business Overview & Revenue Model
Company Description
Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market biological therapies. These treatments are designed to influence the body's immune system, both its inherent and adaptive responses, ther...
Sunho Biologics,Inc. Financial Statement Overview
Summary
Income Statement
15
Very Negative
Balance Sheet
25
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.00K | 38.00K | 17.53M | 1.73M | 3.22M |
| Gross Profit | -5.34M | 38.00K | 138.00K | 473.00K | 3.22M |
| EBITDA | -83.09M | -94.95M | -123.37M | -38.11M | -64.21M |
| Net Income | -82.09M | -79.97M | -132.70M | -51.99M | -70.63M |
Balance Sheet | |||||
| Total Assets | 557.88M | 560.74M | 290.45M | 70.86M | 84.95M |
| Cash, Cash Equivalents and Short-Term Investments | 441.40M | 457.28M | 210.07M | 1.82M | 10.66M |
| Total Debt | 68.24M | 41.20M | 9.07M | 11.03M | 160.86M |
| Total Liabilities | 76.62M | 48.80M | 394.56M | 72.36M | 216.50M |
| Stockholders Equity | 481.27M | 511.94M | -104.11M | -1.50M | -131.55M |
Cash Flow | |||||
| Free Cash Flow | -64.30M | -158.28M | -41.68M | -36.02M | -58.17M |
| Operating Cash Flow | -22.75M | -109.02M | -40.65M | -34.59M | -52.65M |
| Investing Cash Flow | -312.55M | -345.04M | -83.89M | -1.36M | -10.36M |
| Financing Cash Flow | 19.37M | 406.53M | 255.50M | 27.10M | 64.98M |
Sunho Biologics,Inc. Technical Analysis
Negative
6.59
Price Trends
6.39
Positive
6.39
Positive
6.54
Negative
Market Momentum
>-0.01
Negative
46.98
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2898, the sentiment is Negative. The current price of 6.59 is above the 20-day moving average (MA) of 6.39, above the 50-day MA of 6.39, and above the 200-day MA of 6.54, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.98 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2898.
Sunho Biologics,Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | HK$204.24B | 34.80 | 10.51% | ― | 21.93% | 21.94% | |
70 Outperform | HK$26.93B | 61.04 | 15.79% | ― | 48.04% | 166.72% | |
65 Neutral | HK$68.87B | -13.44 | -16.23% | 0.35% | 53.48% | -120.02% | |
64 Neutral | HK$38.22B | 37.75 | 20.41% | ― | 32.63% | 8.87% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
46 Neutral | HK$34.66B | -78.10 | -7.32% | ― | 34.83% | 58.94% | |
41 Neutral | HK$970.43M | -8.84 | -39.21% | ― | ― | ― |
* General Sector Average
HK:2898
Sunho Biologics,Inc.
6.39
-1.44
-18.39%
HK:1548
Genscript Biotech
31.00
13.55
77.65%
HK:2269
Wuxi Biologics (Cayman)
48.48
10.82
28.73%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.66
-19.18
-52.06%
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
58.00
32.44
126.92%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
65.55
-20.35
-23.69%
Sunho Biologics,Inc. Corporate Events
Sunho Biologics Sets New Board and Committee Line-Up
Jul 21, 2026
Sunho Biologics, Inc., incorporated in the Cayman Islands and listed in Hong Kong under stock code 2898, operates in the biotechnology and life sciences sector. The company is focused on developing biological products, and its governance structure...
Sunho Biologics Director to Exit as Share Trading Suspension Persists
Jul 21, 2026
Sunho Biologics has announced that non-executive director Fan Rongkui will leave the board when his service contract expires on July 22, 2026. The company stated that Fan has no disagreements with the board based on information currently available...
Sunho Biologics Shareholders Approve Auditor Switch at Extraordinary Meeting
Jun 29, 2026
Sunho Biologics, Inc. shareholders convened an extraordinary general meeting on June 29, 2026, where they voted on changes to the company’s external auditors. All 156,666,800 issued shares were eligible to vote, and no shareholders were requ...
Sunho Biologics outlines progress on investigation, controls ahead of trading resumption
Jun 29, 2026
Sunho Biologics has provided a quarterly update on its efforts to resume trading of its shares on the Hong Kong Stock Exchange following delays in publishing its 2025 annual results and a resulting suspension. The company has appointed CLA Advisor...
Sunho Biologics Names Forensic Investigator as Trading Suspension Persists
Jun 17, 2026
Sunho Biologics, Inc. has appointed CLA Advisory (Hong Kong) Limited as an independent forensic investigator to conduct a probe into previously identified matters that led to delayed publication of its 2025 annual results. The investigator, select...
Sunho Biologics Calls EGM to Approve Change of Auditor
Jun 8, 2026
Sunho Biologics, Inc. has called an extraordinary general meeting for June 29, 2026 in Nanjing to seek shareholder approval relating to changes in its external audit arrangements. The meeting will confirm and ratify the resignation of ZHONGHUI AND...
Sunho Biologics Replaces Auditor Amid Delay in 2025 Results and Listing Risk
Jun 5, 2026
Sunho Biologics has announced the resignation of its auditor Zhonghui Anda, effective June 5, 2026, after the firm was unable to complete the audit work needed to finalize the company’s 2025 annual results. The delay has left the results out...
Sunho Biologics Sets Up Independent Probe as Trading Suspension Persists
May 26, 2026
Sunho Biologics has formed an Independent Investigation Committee, composed of three independent non-executive directors and chaired by Anthony Chan Heung Wing, to conduct a forensic investigation into matters linked to the company’s delayed...
Sunho Biologics Ordered to Meet Strict Conditions for Share Trading Resumption
May 3, 2026
Sunho Biologics has received formal resumption guidance from the Hong Kong Stock Exchange after trading in its shares was suspended due to delays in publishing its 2025 annual results and related governance concerns. The exchange has ordered an in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.